UBI Pharma Inc.
Quick facts
Marketed products
- Eprex · Other
Phase 3 pipeline
- UB-851 · Diabetes
UB-851 is a small molecule that targets the SGLT2 receptor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: